CClinicalTrials.gg
CompletedNCT04686552CINNIUpdated Dec 28, 2020

Effect Cinnamon Spice on Postprandial Glucose and Insulin Responses

An interventional study of cinnamon in Normal Weight and Overweight and Obesity, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-28.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Jan 2018, registered Dec 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The objective of the proposed study is to investigate the effect of cinnamon on the postprandial glycemic response to a high glycemic index meal in normal and overweight/obese prediabetic subjects

Read the detailed description

A randomized crossover study design will be carried out in accordance with the guidelines of the Human Subjects Protection Committee of the University of California, Los Angeles. All subjects will give written informed consent before the study begins. There will be two groups of participants (normal and overweight/obese). Each participant will consume oatmeal prepared with 1 cup of 2% milk served with or without 6 g of ground cinnamon in random sequence. At each meal consumption blood will be collected to measure postprandial glucose and insulin at 0, 30, 60, 90, 120, 150 and 180 minutes.

02

Conditions studied

  • Normal Weight
  • Overweight and Obesity

Browse trials for

Keywords

  • cinnamon
  • insulin
  • glucose
  • postprandial
  • acute
03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.

This study's enrollment of 32 is below the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy human adults age 20-50 years' old
  • Typically consume low fiber/polyphenol diet (beige diet)
  • normal weight individuals with a BMI of 18. to 24.9 kg/ m2 with fasting serum glucose \<100 mg/dL
  • overweight/obese individuals with a BMI of 25 to 35 kg/m2 and fasting serum glucose ≥100 mg/dL and \<126 mg/dL or HbA1c >5.7% and \< 6.5%.
  • Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.

Exclusion criteria

Exclusion Criteria:

  • Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.
  • Any subject currently taking blood thinning medications such as Warfarin or Coumadin
  • Any history of gastrointestinal disease or surgery except for appendectomy or cholecystectomy.
  • Eating a high fiber/polyphenol diet or taking any medication or dietary supplement which interfere with the absorption of polyphenols.
  • History of gastrointestinal surgery, diabetes mellitus, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP >160mmHg, diastolic BP >95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history.
  • Pregnant or breastfeeding
  • Currently uses tobacco products.
  • Currently has an alcohol intake > 20 g ⁄ day;
  • Currently has a coffee intake > 3 cups ⁄ day;
  • Allergy or sensitivity to cinnamon. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. To determine this, a positive history of cinnamon ingestion without incident will be requested. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded
  • Is lactose intolerant
  • Is unable or unwilling to comply with the study protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    cinnamon

    The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served with 6 g of ground cinnamon.

    Dietary Supplement: cinnamon

  • No intervention
    control

    The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served without 6 g of ground cinnamon

Interventions

  • Dietary supplementcinnamon

    6 g of ground cinnamon

    Also known as: control

06

What researchers measure

Primary outcomes

  1. glucose

    postprandial glucose reponse

    Time frame: Baseline to 180 minutes

  2. insulin

    postprandial insulin response

    Time frame: Baseline to 180 minutes

Secondary outcomes

  1. C-peptide

    postprandial C-peptide response

    Time frame: Baseline to 180 minutes

  2. glucagon

    postprandial glucagon reponse

    Time frame: Baseline to 180 minutes

  3. lipids

    postprandial lipid response

    Time frame: Baseline to 180 minutes

07

Study locations

1 site
  • UCLA Center for Human Nutrition
    Los Angeles, California 90024, United States
08

References and documents

Publications

  • Wang J, Wang S, Yang J, Henning SM, Ezzat-Zadeh Z, Woo SL, Qin T, Pan Y, Tseng CH, Heber D, Li Z. Acute Effects of Cinnamon Spice on Post-prandial Glucose and Insulin in Normal Weight and Overweight/Obese Subjects: A Pilot Study. Front Nutr. 2021 Jan 21;7:619782. doi: 10.3389/fnut.2020.619782. eCollection 2020. PubMed 33553233 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04686552
Lead sponsor
University of California, Los Angeles
Responsible party
Zhaoping Li (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Dec 28, 2020
Start date
Jan 1, 2018
Primary completion
Jan 1, 2019
Completion
Jan 1, 2020
Last update
Dec 28, 2020

Study contacts

Zhaoping Li, MD, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion